CAMBRIDGE, MA--(Marketwire - 11/11/09) - Molecular Insight Pharmaceuticals, Inc. (NASDAQ:MIPI - News), announced that John W. Babich, Ph.D., Executive Vice President, Chief Scientific Officer and President of Research and Development, will present an overview of the Company and its pipeline of targeted therapeutic oncology radiopharmaceuticals at the Lazard Capital Markets 6th Annual Healthcare Conference on November 18, 2009 at 3:15 PM, Eastern Standard Time. The presentation will take place at the St. Regis Hotel in New York, New York.

The presentation will be webcast live at http://www.wsw.com/webcast/lz6/mipi/ and it will be archived for 90 days. The webcast also will be available in the Investor Relations section of the Molecular Insight Pharmaceuticals website at www.molecularinsight.com.

About Molecular Insight Pharmaceuticals, Inc.

Molecular Insight Pharmaceuticals is a clinical-stage biopharmaceutical company and pioneer in the emerging field of molecular medicine. The Company is focused on the discovery and development of targeted therapeutic and imaging radiopharmaceuticals, primarily for use in oncology. Molecular Insight has five clinical-stage candidates in development. For further information on Molecular Insight Pharmaceuticals, please visit www.molecularinsight.com.

 
Contact:
Investors
Chuck Abdalian
Chief Financial Officer
(617) 871-6618
cabdalian@molecularinsight.com
Media
Martin A. Reynolds
Manager
Corporate Communications
(617) 871-6734
mreynolds@molecularinsight.com
Susan Pietropaolo
BCC Partners
(845) 638-6290
(201) 923-2049
spietropaolo@bccpartners.com